Altered astrocytic function in experimental neuroinflammation and multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects about 2.5 million people worldwide. In MS, the patients’ immune system starts to attack the myelin sheath, leading to demyelination, neurodegeneration, and, ultimately, loss of vital neurologic...

Full description

Saved in:
Bibliographic Details
Published inGlia Vol. 69; no. 6; pp. 1341 - 1368
Main Authors Neves, Sofia Pereira, Sousa, João Carlos, Sousa, Nuno, Cerqueira, João José, Marques, Fernanda
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2021
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects about 2.5 million people worldwide. In MS, the patients’ immune system starts to attack the myelin sheath, leading to demyelination, neurodegeneration, and, ultimately, loss of vital neurological functions such as walking. There is currently no cure for MS and the available treatments only slow the initial phases of the disease. The later‐disease mechanisms are poorly understood and do not directly correlate with the activity of immune system cells, the main target of the available treatments. Instead, evidence suggests that disease progression and disability are better correlated with the maintenance of a persistent low‐grade inflammation inside the CNS, driven by local glial cells, like astrocytes and microglia. Depending on the context, astrocytes can (a) exacerbate inflammation or (b) promote immunosuppression and tissue repair. In this review, we will address the present knowledge that exists regarding the role of astrocytes in MS and experimental animal models of the disease. Main points Astrocytes lose physiological and gain pathological functions that can be beneficial or detrimental for MS. Astrocytes are a possible therapeutic target in MS. Astrocytes heterogeneity is observed between humans and rodent/non‐human primates.
Bibliography:Funding information
Clinical Academic Center (2CA‐Braga), Grant/Award Number: EXPL/001/2016; Fundação para a Ciência e a Tecnologia, Grant/Award Numbers: CEECIND/01084/2017, EXPL/NEU‐OSD/2196/2013, NORTE‐01‐0145‐FEDER‐000013, PD/BD/114120/2015
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0894-1491
1098-1136
DOI:10.1002/glia.23940